About ultragenyx pharmaceutical - RARE
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.
RARE At a Glance
Ultragenyx Pharmaceutical, Inc.
60 Leveroni Court
Novato, California 94949
| Phone | 1-415-483-8800 | Revenue | 673.00M | |
| Industry | Pharmaceuticals: Major | Net Income | -575,000,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 20.129% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,371 | |
| View SEC Filings |
RARE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.37 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.668 |
| Enterprise Value to Sales | 4.211 |
| Total Debt to Enterprise Value | 0.442 |
RARE Efficiency
| Revenue/Employee | 490,882.567 |
| Income Per Employee | -419,401.896 |
| Receivables Turnover | 4.233 |
| Total Asset Turnover | 0.443 |
RARE Liquidity
| Current Ratio | 2.477 |
| Quick Ratio | 2.341 |
| Cash Ratio | 1.805 |
RARE Profitability
| Gross Margin | 79.792 |
| Operating Margin | -79.495 |
| Pretax Margin | -84.844 |
| Net Margin | -85.438 |
| Return on Assets | -37.886 |
| Return on Equity | -656.029 |
| Return on Total Capital | -49.061 |
| Return on Invested Capital | -52.364 |
RARE Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 106.826 |
| Total Debt to Total Assets | 81.723 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 99.915 |